"Cheryl brings great experience in leading corporate operations, development and strategy, which will position Rapport well to make strides in our ongoing clinical programs in seizure and psychiatric disorders and further the development of our portfolio strategy," said Abraham Ceesay, Chief Executive Officer of Rapport. "And we are proud to welcome Dr. Young to our scientific advisory board, which will benefit from her tremendous expertise in developing new medicines as we work to develop more treatment options for those with neurological disorders."